Search This Website

Saturday, June 20, 2020

Fabiflu : Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tabletIndia

FabiFlu: All you need to know about Glenmark's COVID-19 treatment medicine

Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients, after it received the Indian drug regulator Drug Controller General of India (DCGI) approval.

The drug Favipiravir, under the brand name FabiFlu, will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said in the statement.

The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.

"Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country," he added.

The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its in-house research and development team, Glenmark said.

"We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for COVID-19.

"Second is it has a wide therapeutic safety margin for Covid-19 at the dose that we administer,"Glenmark PharmaceuticalsPresident India Formulations, Middle East and AfricaSujesh Vasudevan said at an online press conference

It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said.

Glenmark Pharmaceuticals Limited has announced the introduction of Favipiravir under the brand name FabiFlu in tablet form for the treatment of mild & moderate coronavirus (COVID-19) cases in India.

Nearly 80% of all COVID-19 positive cases in India are under this category. FabiFlu is India’s first oral antiviral drug for treatment of mild & moderate COVID-19 patients, the company said.

Glenmark’s antiviral drug Fabiflu to be used for patients with mild and moderate symptoms

“It is a significant step in the fight against COVID-19 India. Glenmark is leading the flight. We are not looking it as a business opportunity.

The priority is to make the drug available to as many patients and save lives,” said Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals Limited in a video conference.

ICMR recommends use of faster COVID-19 testing kit

The company had on Friday received approval from Indian drug regulator for manufacturing and marketing of Favipiravir in oral form in India.

On Saturday the company said the drug would be available from the evening near its factory areas and pan India in 7 to 10 days.

No comments:

Post a Comment